| Literature DB >> 26382974 |
Kaori Nakanishi1, Makoto Nishida1, Masaya Harada2, Tohru Ohama1, Noritaka Kawada1, Masaaki Murakami2, Toshiki Moriyama1, Keiko Yamauchi-Takihara1.
Abstract
While aging is unavoidable, the aging mechanism is still unclear because of its complexity. Smoking causes premature death and is considered as an environmental aging accelerator. In the present study, we focused on the influence of smoking to the serum concentration of anti-aging protein α-klotho (αKl) and the β-klotho-associated protein fibroblast growth factor (FGF)-21 in men. Subjects consisted of apparently healthy men over 40 years of age who underwent health examination. Physical and biochemical parameters, including the levels of several cytokines and growth factors, were obtained from the subjects. Among middle-aged men (46.1 ± 5.1 years), serum levels of FGF-21, soluble αKl (sαKl), and inflammation-related cytokine interleukin (IL)-6 were significantly higher in smokers than in never-smokers. Serum levels of FGF-21 increased and correlated with alanine transaminase, γ guanosine-5'-triphosphate, and total cholesterol only in smokers, suggesting FGF-21 as a metabolic disorder-related factor in smokers. In aged men (60.3 ± 1.7 years), although the serum levels of sαKl in never-smokers were low, smokers showed highly increased serum levels of sαKl. Serum levels of sαKl was correlated with IL-6 in middle-aged never-smokers, suggesting sαKl regulates IL-6. However, this correlation was disrupted in smokers and aged men.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26382974 PMCID: PMC4585559 DOI: 10.1038/srep14230
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Characteristics of the study subject.
| All | Smoker | Never-smoker | P-value | |
|---|---|---|---|---|
| (n = 80) | (n = 40) | (n = 40) | ||
| Age (years) | 46.1 ± 5.1 | 46.1 ± 5.0 | 46.1 ± 5.2 | 0.98 |
| BMI (kg/m2) | 23.5 ± 2.8 | 23.9 ± 3.0 | 23.1 ± 2.7 | 0.26 |
| WC (cm) | 82.7 ± 7.3 | 83.3 ± 7.1 | 82.0 ± 7.5 | 0.43 |
| VFA (cm2) | 91.4 ± 34.9 | 94.7 ± 33.7 | 87.3 ± 36.5 | 0.44 |
| SBP (mmHg) | 122 ± 14 | 123 ± 15 | 121 ± 12 | 0.59 |
| DBP (mmHg) | 78 ± 10 | 79 ± 10 | 78 ± 10 | 0.61 |
| Cr (mg/dl) | 0.8 ± 0.1 | 0.8 ± 0.1 | 0.8 ± 0.1 | 0.37 |
| UA (mg/dl) | 6.1 ± 1.3 | 6.2 ± 1.2 | 6.0 ± 1.5 | 0.57 |
| TC (mg/dl) | 206 ± 33 | 209 ± 36 | 203 ± 30 | 0.39 |
| TG (mg/dl) | 114 ± 89 | 125 ± 96 | 104 ± 82 | 0.15 |
| HDL-C (mg/dl) | 58 ± 15 | 59 ± 17 | 57 ± 13 | 0.67 |
| FPG (mg/dl) | 90 ± 19 | 92 ± 26 | 88 ± 6 | 0.37 |
| HbA1c (%) | 5.1 ± 0.8 | 5.2 ± 1.0 | 4.9 ± 0.3 | 0.09 |
| FGF-19 (pg/ml) | 205 ± 157 | 183 ± 117 | 227 ± 188 | 0.67 |
| FGF-21 (pg/ml) | 239 ± 167 | |||
| sαKl (pg/ml) | 500 ± 170 | |||
| IL-6 (pg/ml) | 2.1 ± 0.8 | |||
| APN (μg/ml) | 7.2 ± 3.0 | 6.7 ± 2.7 | 7.9 ± 3.3 | 0.20 |
Data are expressed as mean ± SD. *P < 0.05 versus never-smokers.
BMI, body mass index; WC, waist circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure; VFA, visceral fat area; UA, uric acid; TC, total cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein-cholesterol; FPG, fasting plasma glucose; FGF-19, fibroblast growth factor-19; FGF-21, fibroblast growth factor-21; sαKl, soluble alpha-Klotho; IL-6, interleukin-6; APN, adiponectin.
Details of smoking habit in smokers.
| Smoker (n = 40) | n (%) |
|---|---|
| Cigarettes smoked per day | |
| 10–20 cigarettes | 29 (72.5) |
| 21–30 cigarettes | 8 (20) |
| 31–40 cigarettes | 3 (7.5) |
| Duration of smoking | |
| 5–10 years | 1 (2.5) |
| 11–15 years | 4 (10) |
| 16–20 years | 6 (15) |
| >20 years | 29 (72.5) |
Correlations between fibroblast growth factor (FGF)-21, soluble alpha Klotho (sαKl), and other cytokines.
| FGF-21 | sαKl | |||
|---|---|---|---|---|
| r | P-value | r | P-value | |
| FGF-19 | −0.05 | 0.60 | −0.03 | 0.78 |
| FGF-21 | − | − | −0.06 | 0.46 |
| sαKl | −0.06 | 0.46 | − | − |
| IL-6 | 0.06 | 0.51 | ||
| APN | 0.12 | 0.23 | ||
n = 80, *P < 0.05, **P < 0.001.
Abbreviations are as in Table 1.
Correlations between fibroblast growth factor (FGF)-21 and biochemical parameters.
| Smoker (n = 40) | Never-smoker (n = 40) | |||
| r | P-value | r | P-value | |
| AST | 0.18 | 0.12 | 0.09 | 0.42 |
| ALT | 0.10 | 0.39 | ||
| γGTP | 0.12 | 0.29 | ||
| TC | 0.02 | 0.83 | ||
| TG | 0.22 | 0.06 | 0.04 | 0.73 |
| HDL-C | −0.15 | 0.18 | −0.04 | 0.70 |
| FPG | 0.13 | 0.26 | 0.20 | 0.08 |
| HbA1c | 0.08 | 0.49 | −0.01 | 0.95 |
*P < 0.01, **P < 0.001.
Abbreviations are as in Table 1.
Figure 1Relationship between serum levels of soluble alpha Klotho (sαKl) and environmental stresses.
Relationships between serum levels of sαKl and (A) sleep duration time and (B) psychological stress. Sleep duration time was classified into three periods: ≥6 hours per day, >4 and <6 hours per day, and ≤4 hours per day. Psychological stress was classified into four stages: almost no stress (None), sometimes feel stress (Sometimes), often feel stress (Often), always feel stress (Always). Data are sample minimum, lower quartile, median, upper quartile, and sample maximum. n = 80, *P < 0.05 versus subjects whose sleep duration time were ≥6 hours per day.
Figure 2Correlations between serum levels of soluble alpha Klotho (sαKl) and growth factors.
Correlations between serum levels of sαKl and growth factors. (A) amphiregulin (AREG), (B) epidermal growth factor receptor (EGFR), (C) fibroblast growth factor-basic (FGF-basic), (D) placental growth factor (PLGF), (E) transforming growth factor alpha (TGF-α), and (F) vascular endothelial growth factor (VEGF)-A. n = 80.
Figure 3Correlations between serum levels of soluble alpha Klotho (sαKl) and interleukin (IL)-6 among smokers and never-smokers.
Correlations between serum levels of sαKl and IL-6 in (A) middle-aged smoker (n = 40), (B) middle-aged never-smoker (n = 40), (C) aged smoker (n = 34), and (D) aged never-smoker (n = 26).